Quoin Pharmaceuticals (QNRX) announced the release of the fourth episode in its NETHERTON NOW video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals Reports Q2 2025 Financial Results
- Quoin Pharmaceuticals reports Q2 EPS ($6.28) vs ($13.68) last year
- Buy Rating for Quoin Pharmaceuticals: Promising Developments in Netherton Syndrome Treatment and Strategic Regulatory Advantages
- Quoin Pharmaceuticals provides update on its development product portfolio
- Quoin Pharmaceuticals CFO Departure Announcement